Rheumatology
Rheumatology practices and management organizations treating inflammatory arthritis, lupus, and autoimmune musculoskeletal conditions.
- 5
- Verticals
Overview
Rheumatology practices and management organizations treat inflammatory arthritis, lupus, and autoimmune musculoskeletal conditions. The specialty's economics are increasingly tied to in-office biologic infusion, which provides significant ancillary revenue and has drawn private-equity interest.
Demand is supported by the prevalence of autoimmune and inflammatory conditions and the growth of biologic therapies, against a shortage of rheumatologists. Infusion-driven economics and emerging MSO consolidation define the investment thesis.
Market snapshot
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so rheumatology is not separately sized.
Business model & economics
Revenue model
Office reimbursement plus in-office biologic infusion margin
Key economics
- Recurring revenue
- High
- EBITDA margin
- 18–28% with infusion ancillaries
- Capex intensity
- Low
chronic autoimmune care and infusion
Characteristics
- In-office biologic infusion drives ancillary economics.
- Autoimmune prevalence and biologics growth.
- Rheumatologist shortage and emerging MSO interest.
M&A deal context
Who’s acquiring
- Infusion-focused MSO platforms
- PE-backed rheumatology consolidators
- Multispecialty acquirers
What’s driving deals
- Roll-up for infusion ancillary economics.
- Autoimmune and biologics demand.
- Rheumatologist shortage.
Verticals in this segment
Find Rheumatology acquisition targets
Search Acquisera’s index for companies classified under Rheumatology (4.10.25) and build a targeted deal pipeline.
Search companies